GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » EV-to-EBIT

Cantargia AB (OSTO:CANTA) EV-to-EBIT : -3.03 (As of Jun. 08, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cantargia AB's Enterprise Value is kr729.17 Mil. Cantargia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-240.76 Mil. Therefore, Cantargia AB's EV-to-EBIT for today is -3.03.

The historical rank and industry rank for Cantargia AB's EV-to-EBIT or its related term are showing as below:

OSTO:CANTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.73   Med: 0   Max: 0
Current: -3.03

OSTO:CANTA's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.8 vs OSTO:CANTA: -3.03

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cantargia AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr498.46 Mil. Cantargia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-240.76 Mil. Cantargia AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -48.30%.


Cantargia AB EV-to-EBIT Historical Data

The historical data trend for Cantargia AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB EV-to-EBIT Chart

Cantargia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.89 -31.83 -3.52 -0.24 -1.76

Cantargia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 -1.32 -1.71 -1.76 -2.07

Competitive Comparison of Cantargia AB's EV-to-EBIT

For the Biotechnology subindustry, Cantargia AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cantargia AB's EV-to-EBIT falls into.



Cantargia AB EV-to-EBIT Calculation

Cantargia AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=729.173/-240.759
=-3.03

Cantargia AB's current Enterprise Value is kr729.17 Mil.
Cantargia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-240.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantargia AB  (OSTO:CANTA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cantargia AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-240.759/498.46363
=-48.30 %

Cantargia AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr498.46 Mil.
Cantargia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-240.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantargia AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cantargia AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB (OSTO:CANTA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB (OSTO:CANTA) Headlines

No Headlines